| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On December 14, 2007
|
|
|
|
|
|
|
|
|
|
|
| Docket
#
|
| Title
|
|
|
|
|
|
|
| 2006F-0409
|
| Safe Use of Cetylpyridinium Chloride as an Antimicrobial Agent in a Pre-chiller or Post-chiller Solution for Application to Raw Poultry Carcasses (FAP 6A4767)
|
|
|
|
|
| 2006N-0168
|
| Food Labeling: Reference Daily Intakes & Daily Reference Values
|
|
|
|
|
| 2006N-0221
|
| Requirements for Human Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use
|
|
|
|
|
| 2007D-0386
|
| Guidance for Industry on Postmarketing Adverse Event Reporting for Nonprescription Human Drug Products Marketed Without an Approved Application
|
|
|
|
|
| 2007D-0387
|
| GIn Vitro Diagnostic Device Studies Frequently Asked Questions;Guidance for Industry and FDA Staff
|
|
|
|
|
| 2007D-0388
|
| Guidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protec
|
|
|
|
|
|
|
|
|
| 2007D-0396
|
| Drug-Induced Liver Injury: Premarketing Clinical Evaluation;Draft Guidance
|
|
|
|
|
| 2007N-0280
|
| Amendment to the CGMP Regulations for Finished Pharmaceuticals
|
|
|
|
|
| 2007N-0356
|
| BEHIND THE COUNTER AVAILABILITY OF CERTAIN DRUGS; Public Meeting
|
|
|
|
|
| 2007P-0438
|
| Declare Angel Parfum, Angel Eau du Toilette and other Angel related fragranced products be declared misbranded and have their importation ceased until their safety can be independently verified
|
|
| |
|
| 2006F-0409
|
| Safe Use of Cetylpyridinium Chloride as an Antimicrobial Agent in a Pre-chiller or Post-chiller Solution for Application to Raw Poultry Carcasses (FAP 6A4767)
|
|
|
|
|
| EC 9
|
| Miss. erin young
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006N-0168
|
| Food Labeling: Reference Daily Intakes & Daily Reference Values
|
|
|
|
|
| EXT 4
|
| Food Products Association
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006N-0221
|
| Requirements for Human Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use
| |
|
|
|
| EC 7
|
| PPTA
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 8
|
| Puget Sound Blood Center
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007D-0386
|
| Guidance for Industry on Postmarketing Adverse Event Reporting for Nonprescription Human Drug Products Marketed Without an Approved Application
|
|
|
|
|
| C 1
|
| Johnson & Johnson
|
| Vol #:
|
| 1
|
|
|
|
|
| C 2
|
| American Herbal Products Association
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007D-0387
|
| GIn Vitro Diagnostic Device Studies Frequently Asked Questions;Guidance for Industry and FDA Staff
|
|
|
|
|
| C 1
|
| Eli Lilly and Company
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007D-0388
|
| Guidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protec
|
|
|
|
|
|
| |
|
|
|
| C 1
|
| American Herbal Products Association
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 2
|
| Natural Products Association
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 3
|
| Center for Science in the Public Interest
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 4
|
| CHPA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007D-0396
|
| Drug-Induced Liver Injury: Premarketing Clinical Evaluation;Draft Guidance
|
|
|
|
|
| EC 1
|
| AstraZeneca LP
|
| Vol #:
|
| 1
|
|
| |
|
| 2007N-0280
|
| Amendment to the CGMP Regulations for Finished Pharmaceuticals
|
|
